Cellectis (NASDAQ:CLLS) Releases Quarterly Earnings Results
Cellectis (NASDAQ:CLLS) reported its quarterly earnings, posting a loss of ($0.18) per share. The biotechnology company has a negative net margin of 234.39% and a negative return on equity of 74.55%. Shares traded down 4.4% to $1.51, with a market cap of $83.93 million. Analyst ratings have upgraded Cellectis from "hold" to "buy". The company focuses on developing immuno-oncology products targeting cancer cells.
Cellectis (NASDAQ:CLLS - Get Free Report) announced its quarterly earnings results on Monday. The biotechnology company reported ($0.18) earnings per share for the quarter, Zacks reports. Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%.
Cellectis Trading Down 4.4%
- Cellectis Charts Course for 2025 With Boost From AstraZeneca Deal
Shares of NASDAQ CLLS traded down $0.07 during trading on Monday, hitting $1.51. 24,659 shares of the company were exchanged, compared to its average volume of 142,061. The company has a fifty day moving average price of $1.36 and a 200-day moving average price of $1.59. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.78 and a current ratio of 1.78. The firm has a market capitalization of $83.93 million, a PE ratio of -1.16 and a beta of 3.11. Cellectis has a 12-month low of $1.10 and a 12-month high of $3.10.
Analyst Ratings Changes
Separately, StockNews.com upgraded Cellectis from a "hold" rating to a "buy" rating in a research note on Friday, April 25th.
Read Our Latest Analysis on Cellectis
Cellectis Company Profile
(Get Free Report)Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.
Further Reading
- Five stocks we like better than Cellectis
- How to Calculate Stock Profit
- Palantir’s Latest Deal Could Put a Freeze on Its Stock Price
- CD Calculator: Certificate of Deposit Calculator
- 4 Automaker Stocks React to Tariffs: Winners and Losers
- Pros And Cons Of Monthly Dividend Stocks
- Here's Why Call Option Traders Love Dutch Bros Stock
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Cellectis Right Now?
Before you consider Cellectis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellectis wasn't on the list.
While Cellectis currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
